Study of Obeldesivir as Postexposure Prophylaxis for Filovirus Diseases Virus Disease

Summary

The goal of this clinical study is to learn more about the study drug, obeldesivir (ODV), and how safe and effective it is preventing Filovirus disease in participants with known or suspected exposure to Filovirus disease. The primary objective is to evaluate the safety and tolerability of ODV for Ebola virus (EBOV), Sudan virus (SUDV), and MARV postexposure prophylaxis (PEP).

Timeline

Start

2025-12

Primary completion

2025-12

Completion

2025-12

Outcome

Outcome not reported

Stopped (Enrollment): “The study was withdrawn after the Marburg outbreak in Rwanda was declared over, prior to enrollment of any participants.”

Drugs

Indications